ArticleBMC endocrine disorders2020
Effect of metastatic site on survival in patients with neuroendocrine neoplasms (NENs). An analysis of SEER data from 2010 to 2014.
Article in BMC endocrine disorders, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Challenges in the management of bone metastases: focus on differentiated thyroid cancer and neuroendocrine tumors.Journal of the Endocrine Society · 2026Article
- Yttrium-90 Radioembolization Versus Transarterial Embolization for Lung Carcinoid Hepatic Metastasis.JTO clinical and research reports · 2026Article
- The Role of Primary Tumor Resection in Surgical Management of Asymptomatic Metastatic PNETs: A Retrospective Single-Center Study.Annals of surgical oncology · 2026Article
- Cardiac Metastases in Neuroendocrine Neoplasms: A Single-Center Experience of Clinical Characteristics and Outcomes.Cancers · 2025Article
- Impact on symptoms and survival of bone metastases in patients with small-intestinal neuroendocrine tumours.Journal of neuroendocrinology · 2025Article
- Automated machine learning predicts liver metastases in patients with early-onset gastroenteropancreatic neuroendocrine tumors.Journal of gastrointestinal oncology · 2025Article
- Machine learning predicts prognosis in patients with gastroenteropancreatic neuroendocrine tumors with liver metastases.Discover oncology · 2025Article
- Article
- [Crosstalk between Tumor Cells and Neural Signals in Neuroendocrine Carcinoma Metastasis: Communication Hijacking Based Perspective].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2025Review
- Genetic dysregulation of EP300 in cancers in light of cancer epigenome control - targeting of p300-proficient and -deficient cancers.Molecular therapy. Oncology · 2024Review
- Liver metastases in high-grade neuroendocrine neoplasms: A comparative study of hepatic tumor volume and biochemical findings in NET G3 versus NEC.Journal of neuroendocrinology · 2024Article
- Models using comprehensive, lesion-level, longitudinal [European journal of nuclear medicine and molecular imaging · 2024Article
- The Molecular Biology of Midgut Neuroendocrine Neoplasms.Endocrine reviews · 2024Review
- Optimal Lymphadenectomy in Patients with Well-Differentiated Nonfunctioning Pancreatic Neuroendocrine Neoplasms.Journal of clinical medicine · 2023Article
- Malignant behavior of a well‑differentiated digestive neuroendocrine tumor with peritoneal carcinomatosis: A case report.Experimental and therapeutic medicine · 2023Article
- DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms.The oncologist · 2022Review
- The Management and Outcomes of Patients with Extra-Pulmonary Neuroendocrine Neoplasms and Brain Metastases.Current oncology (Toronto, Ont.) · 2022Article
- Neuroendocrine neoplasia and bone (Review).Experimental and therapeutic medicine · 2021Review
- Resection of Non-Functional Pancreatic Neuroendocrine Neoplasms-A Single-Center Retrospective Outcome Analysis.Current oncology (Toronto, Ont.) · 2021Article
- A Clinical Nomogram for Predicting Cancer-Specific Survival in Pulmonary Large-Cell Neuroendocrine Carcinoma Patients: A Population-Based Study.International journal of general medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundNeuroendocrine neoplasms (NENs) display variable behaviors based on origin and grade. We assumed that both tumor origin and the location of metastasis may play a role in survival.
methodsWe queried the SEER database (2010-2014) for patients with an established diagnosis of NENs and documented site of metastasis and identified 2005 patients. Overall survival (OS) at the time points were estimated by the Kaplan-Meier method Cox proportional-hazards models were used to evaluate the relationship of the interested variables and OS.
resultsLung, liver, bone and brain metastases were observed in 9, 77, 7 and 6% of metastatic patients respectively. In the multivariate model, metastasis locations were significantly associated with worse survival (liver HR: 1.677 (1.226-2.294); (bone metastasis HR: 1.412 (0.965-2.065); brain HR: 1.666 (1.177-2.357)). We produced a scoring system based on site of origin, metastasis location, age, gender, histology and tumor size that can stratify metastatic NEN patients in low, intermediate and high-risk categories to help physicians with decision making.
conclusionSite of metastasis plays an important role in survival of metastatic NEN patients independent of commonly described prognostic factors and should be considered in survival estimates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.